Abstract
Population studies reveal HLA class I and class II gene polymorphisms associated with all the common chronic autoimmune diseases, notably spondylarthropathies, rheumatoid arthritis, multiple sclerosis and type I diabetes. We here discuss the exceptionally high levels of nucleotide diversity in the MHC region likely to reflect not only balancing selection acting on the epitope binding sites but also natural selection operating on the promoter region. The latter possibility is supported by functional studies with promoters, higher levels of diversity in the promoters of class II than class I genes and the relatively high frequency of single nucleotide polymorphisms around transcription factor binding sites. This, we argue, reflects the need for an appropriate level of signalling at the immunological synapse. We here summarise our knowledge of HLA promoter polymorphisms and how these translate into differential expression, T cell polarisation and inflammation. We discuss current strategies for pharmaceutical intervention in HLA expression.
Keywords: Promoter polymorphism, differential expression
Current Pharmaceutical Design
Title: The Role of HLA Promoters in Autoimmunity
Volume: 12 Issue: 29
Author(s): Brigitte Muller-Hilke and N. Avrion Mitchison
Affiliation:
Keywords: Promoter polymorphism, differential expression
Abstract: Population studies reveal HLA class I and class II gene polymorphisms associated with all the common chronic autoimmune diseases, notably spondylarthropathies, rheumatoid arthritis, multiple sclerosis and type I diabetes. We here discuss the exceptionally high levels of nucleotide diversity in the MHC region likely to reflect not only balancing selection acting on the epitope binding sites but also natural selection operating on the promoter region. The latter possibility is supported by functional studies with promoters, higher levels of diversity in the promoters of class II than class I genes and the relatively high frequency of single nucleotide polymorphisms around transcription factor binding sites. This, we argue, reflects the need for an appropriate level of signalling at the immunological synapse. We here summarise our knowledge of HLA promoter polymorphisms and how these translate into differential expression, T cell polarisation and inflammation. We discuss current strategies for pharmaceutical intervention in HLA expression.
Export Options
About this article
Cite this article as:
Muller-Hilke Brigitte and Mitchison N. Avrion, The Role of HLA Promoters in Autoimmunity, Current Pharmaceutical Design 2006; 12 (29) . https://dx.doi.org/10.2174/138161206778559759
DOI https://dx.doi.org/10.2174/138161206778559759 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Human Platelet Acetylcholinesterase Inhibition by Cyclophosphamide: A Combined Experimental and Computational Approach
CNS & Neurological Disorders - Drug Targets Interconnection of Estrogen/Testosterone Metabolism and Mevalonate Pathway in Breast and Prostate Cancers
Current Molecular Pharmacology New Insights in the Mechanism of Bone Loss in Arthritis
Current Pharmaceutical Design Tuberculous Pericarditis
Current Cardiology Reviews Cytochrome P450 Structure, Function and Clinical Significance: A Review
Current Drug Targets Comparison of Idiopathic Interstitial Pneumonias with Their Connective Tissue Disease-Associated Counterparts
Current Respiratory Medicine Reviews A Key Role for Altered Dendritic Cell Functioning in the Impaired Immunity Seen in Aged Individuals
Current Immunology Reviews (Discontinued) Implication of Heat Shock Protein 90 (HSP90) in Tumor Angiogenesis: A Molecular Target for Anti-Angiogenic Therapy?
Current Cancer Drug Targets Tankyrase as a Novel Molecular Target in Cancer and Fibrotic Diseases
Current Drug Targets Insights into Targeting NEMO for Pharmacological Regulation
Current Drug Targets Nanomaterial Based Affinity Matrix-Assisted Laser Desorption/Ionization Mass Spectrometry for Biomolecules and Pathogenic Bacteria
Recent Patents on Nanotechnology Clinical Experience with Specific COX-2 Inhibitors in Arthritis
Current Pharmaceutical Design MicroRNAs Involved in Oxidative Stress Processes Regulating Physiological and Pathological Responses
MicroRNA Atypical Chemokine Receptors in Inflammatory Disease
Current Molecular Medicine Oxidation Inhibits Iron-Induced Blood Coagulation
Current Drug Targets Depression as a Comorbidity in Behcet's Syndrome
CNS & Neurological Disorders - Drug Targets Neurological Effects of SARS-CoV-2 and Neurotoxicity of Antiviral Drugs Against COVID-19
Mini-Reviews in Medicinal Chemistry Prevalence and Risk Factors of Vitamin D Deficiency in Critically Ill Patients
Inflammation & Allergy - Drug Targets (Discontinued) Proteoglycan Involvement in Inflammatory Diseases. New Developments in GAG-Based Therapies
Medicinal Chemistry Reviews - Online (Discontinued) Phosphonic Esters and their Application of Protease Control
Current Pharmaceutical Design